None listed
Conditions
Interventions
Procedure/Surgery : 1. Electroacupuncture and Electronic Moxibustion + Alpha blocker group
- Patients receive electroacupuncture and electronic moxibustion treatment 3 times a week for a total of 6 we
Sponsors
Korea Institute of Oriental Medicine
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) Man over 50 years old and under 79 years old who is diagnosed with prostatic hyperplasia and is taking alpha blocker 2) Total International Prostate Symptom Score (Total IPSS) is 8 or more and 19 or less 3) Able and willing to comply with the intervention and follow-up evaluation 4) Able to provide written informed consent
Exclusion criteria
Exclusion criteria: 1) Subjects who are diagnosed with prostatic hyperplasia and are taking medications other than alpha blockers (5-alpha reductase inhibitors, anticholinergic drugs, antidiuretic hormones, etc.) for treatment 2) Subjects whose Prostate-Specific Antigen (PSA) values are greater than 4ng/mL (subjects with a PSA = 4ng/mL are required to have a prostate biopsy negative for malignance) 3) Subjects with the clinical evidence of neurogenic bladder, urethral stricture, bladder calculus, acute/chronic renal failure, urinary tract infection or other urology diseases except BPH 4) Subjects with clinical evidence of genito-urinary malignant tumors including prostate or bladder cancer 5) Subjects who have history of prostate surgery or who are scheduled prostate surgery 6) Subjects who had AUR 7) Subjects with clinical evidence of renal or hepatic impairment 8) Subjects with clinically significant urinalysis findings or hematuria with urinalysis 9) Subjects who use pacemaker 10) Severe underlying disease (uncontrolled hypertention, cardiovascular disease, or malignant tumor) requiring active therapy 11) Subjects with uncontrolled diabetes or diabetic neuropathy 12) Subjects with local skin disease at the site of electronic moxibustion 13) History of neurotic or major psychiatric disability or cognitive instability 14) Subjects who are considered to be inappropriate for the study by the researcher
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total International Prostate Symptom Score(IPSS) change after 6 weeks from baseline | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety assessment(Adverse effect);Total International Prostate Symptom Score(IPSS) change after 3 weeks, 12 weeks from baseline;Clinical relevance (MCID ratio);Prostate volume;Quality of Life(IPSS life satisfaction, EQ-5D);Maximum flow rate;Average flow rate | — |
Countries
Korea, Republic of
Contacts
Public ContactJu Jeon
Daejeon University
Outcome results
None listed